WO2011077451A3 - Controlled release pharmaceutical composition - Google Patents

Controlled release pharmaceutical composition Download PDF

Info

Publication number
WO2011077451A3
WO2011077451A3 PCT/IN2010/000829 IN2010000829W WO2011077451A3 WO 2011077451 A3 WO2011077451 A3 WO 2011077451A3 IN 2010000829 W IN2010000829 W IN 2010000829W WO 2011077451 A3 WO2011077451 A3 WO 2011077451A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
core
drug
pharmaceutical composition
release pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2010/000829
Other languages
French (fr)
Other versions
WO2011077451A2 (en
Inventor
Sanjay Boldhane
Shripad Jathar
Maneesh Nerurkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Pvt Ltd
Original Assignee
Abbott Healthcare Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Pvt Ltd filed Critical Abbott Healthcare Pvt Ltd
Priority to US13/515,482 priority Critical patent/US20130171199A1/en
Priority to MX2012007448A priority patent/MX2012007448A/en
Priority to BR112012015282A priority patent/BR112012015282A2/en
Priority to EP10838833.1A priority patent/EP2515882A2/en
Priority to RU2012131158/15A priority patent/RU2012131158A/en
Publication of WO2011077451A2 publication Critical patent/WO2011077451A2/en
Publication of WO2011077451A3 publication Critical patent/WO2011077451A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

An oral controlled release pharmaceutical composition comprising a core and a polymer dispersion and its preparation method are disclosed. The core is selected from the group consisting of 'the drug coated core' and 'the drug loaded core'. The drug coated core comprises an inert excipient based sphere and a coat of drug composition. The drug loaded core comprises at least a drug, a binder and at least one pharmaceutically acceptable excipient. The polymer dispersion used to coat the core comprises at least one controlled release polymer and at least one pharmaceutically acceptable excipient. The oral controlled release pharmaceutical composition further comprises an in-situ gelling system comprising at least one gelling polymer.
PCT/IN2010/000829 2009-12-22 2010-12-20 Controlled release pharmaceutical composition Ceased WO2011077451A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/515,482 US20130171199A1 (en) 2009-12-22 2010-12-20 Controlled release pharmaceutical composition
MX2012007448A MX2012007448A (en) 2009-12-22 2010-12-20 Controlled release pharmaceutical composition.
BR112012015282A BR112012015282A2 (en) 2009-12-22 2010-12-20 controlled release pharmaceutical composition
EP10838833.1A EP2515882A2 (en) 2009-12-22 2010-12-20 Controlled release pharmaceutical composition
RU2012131158/15A RU2012131158A (en) 2009-12-22 2010-12-20 PHARMACEUTICAL COMPOSITION WITH CONTROLLED MEDICINAL RELEASE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2955MU2009 2009-12-22
IN2955/MUM/2009 2009-12-22

Publications (2)

Publication Number Publication Date
WO2011077451A2 WO2011077451A2 (en) 2011-06-30
WO2011077451A3 true WO2011077451A3 (en) 2011-10-06

Family

ID=44196219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000829 Ceased WO2011077451A2 (en) 2009-12-22 2010-12-20 Controlled release pharmaceutical composition

Country Status (6)

Country Link
US (1) US20130171199A1 (en)
EP (1) EP2515882A2 (en)
BR (1) BR112012015282A2 (en)
MX (1) MX2012007448A (en)
RU (1) RU2012131158A (en)
WO (1) WO2011077451A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US11504345B2 (en) 2014-05-01 2022-11-22 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
KR101340733B1 (en) * 2012-12-31 2013-12-12 (주) 에프엔지리서치 Novel microgranule preparations
MX378261B (en) * 2013-03-14 2025-03-10 Redhill Biopharma Ltd Antiemetic extended release solid dosage forms
CA2947528C (en) 2014-05-01 2023-09-05 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
WO2016003181A1 (en) * 2014-06-30 2016-01-07 한미약품 주식회사 Composite preparation comprising active ingredient-containing film coating layer
PT3162363T (en) * 2014-06-30 2020-02-21 Hanmi Pharm Ind Co Ltd Composite preparation comprising active ingredient-containing film coating layer
WO2016003180A1 (en) * 2014-06-30 2016-01-07 한미약품 주식회사 Composite preparation comprising 5-α-reductase inhibitor-containing film coating layer, and method for producing the composite preparation
BR112017001968A2 (en) 2014-07-30 2017-11-21 Sun Pharmaceutical Ind Ltd two-chamber packaging for a multi-dose oral liquid pharmaceutical composition
ITUA20161799A1 (en) 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE INCLUDING CISTEAMINE OR ITS SALT
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
WO2022191957A1 (en) * 2021-03-09 2022-09-15 Tulex Pharmaceuticals, Inc. Extended-release compositions comprising atomoxetine
CN116617189B (en) * 2023-07-26 2023-09-26 四川尚锐生物医药有限公司 Duloxetine hydrochloride sustained-release capsule and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1554346A (en) * 2003-12-23 2004-12-15 广州市医药工业研究所 Diltiazem hydrochloride control release capsule and its preparing method
CN1652755A (en) * 2002-04-09 2005-08-10 弗拉梅技术公司 Active ingredient microencapsulated oral suspension
CN1652781A (en) * 2002-04-09 2005-08-10 弗拉梅技术公司 Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin
CN101129384A (en) * 2007-09-06 2008-02-27 河南天方药业股份有限公司 Method for preparing carbamazepine sustained-release capsules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1652755A (en) * 2002-04-09 2005-08-10 弗拉梅技术公司 Active ingredient microencapsulated oral suspension
CN1652781A (en) * 2002-04-09 2005-08-10 弗拉梅技术公司 Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin
CN1554346A (en) * 2003-12-23 2004-12-15 广州市医药工业研究所 Diltiazem hydrochloride control release capsule and its preparing method
CN101129384A (en) * 2007-09-06 2008-02-27 河南天方药业股份有限公司 Method for preparing carbamazepine sustained-release capsules

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504345B2 (en) 2014-05-01 2022-11-22 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
US11523996B2 (en) 2014-05-01 2022-12-13 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions

Also Published As

Publication number Publication date
RU2012131158A (en) 2014-01-27
EP2515882A2 (en) 2012-10-31
US20130171199A1 (en) 2013-07-04
WO2011077451A2 (en) 2011-06-30
BR112012015282A2 (en) 2016-03-15
MX2012007448A (en) 2012-09-12

Similar Documents

Publication Publication Date Title
WO2011106416A3 (en) Abuse-resistant formulations
WO2008022932A3 (en) Controlled release system and method for manufacturing the same
WO2011084593A3 (en) Abuse-resistant formulations
WO2005117843A3 (en) Sustained release preparations
RU2012131158A (en) PHARMACEUTICAL COMPOSITION WITH CONTROLLED MEDICINAL RELEASE
WO2008084698A1 (en) Tacrolimus sustained release pharmaceutical composition
WO2007139886A3 (en) Duloxetine hydrochloride delayed release formulations
WO2009129300A3 (en) Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
NZ610701A (en) Once daily formulation of lacosamide
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2009090670A3 (en) Stabilized sustained release composition of bupropion hydrochloride and process for preparing the same
NZ587897A (en) Drug delivery systems comprising weakly basic drugs and organic acids
WO2008152115A3 (en) Drug-releasing polyelectrolyte coating, method for forming a drug-releasing polyelectrolyte coating, and implantable device
WO2009001043A3 (en) Duloxetine formulation
WO2007054976A3 (en) Lipid based controlled release pharmaceutical composition
WO2011119477A3 (en) Pharmaceutical compositions of carvedilol salts and process for preparation thereof
WO2007020259A3 (en) Controlled release pharmaceutical compositions for acid labile drugs
WO2008113901A3 (en) Composition with controlled release of levetiracetam and method for preparing same
WO2014081581A3 (en) Highly loaded amorphous efavirenz composition and process for preparing the same
MX2009008197A (en) Extended-release dosage form.
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
WO2010121600A3 (en) Particulate pharmaceutical composition having an opioid and an opioid antagonist
GB201202433D0 (en) Controlled drug release
WO2011141791A3 (en) Extended release formulations of desvenlafaxine base

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10838833

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 13515482

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2010838833

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/007448

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: DZP2012000517

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2012131158

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012015282

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012015282

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120621